Vanguard Global Advisers
NVAX icon

Vanguard Global Advisers’s Novavax NVAX Stock Holding History

Vanguard Global Advisers’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602K Hold
63,935
– – ﹤0.01% 2017
2026
Q1 		$520K Buy
+63,935
New +$580K ﹤0.01% 2023

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Vanguard Global Advisers's NVAX Position: Q2 2026 in Review

Vanguard Global Advisers held its Novavax (NVAX) position steady in Q2 2026 at 63,935 shares worth $602K. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Vanguard Global Advisers first reported a position in NVAX in Q1 2026 and has held it in 2 quarters since. 264 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Vanguard Global Advisers held 63,935 shares of Novavax worth $602K as of Q2 2026.
  • Vanguard Global Advisers left its Novavax share count unchanged in Q2 2026.
  • Novavax made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2017 holding.
  • Vanguard Global Advisers first reported a position in Novavax in Q1 2026 and has held it in 2 quarters since.
  • 264 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.